← BioArctic AB Series B overview

BioArctic AB Series B vs ACADIA Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BioArctic AB Series B (0RV2.LSE)

Q3 2026
▲3

Lilly deal, Leqembi at-home approval and 43% royalty growth lift BioArctic

  • Lilly BrainTransporter deal brings $30M upfront and up to $770M milestones BioArctic signed a research deal with Eli Lilly combining its BrainTransporter brain-delivery technology with a Lilly neurodegeneration drug. It gets $30 million cash now and could receive up to $770 million more if milestones are met, plus royalties on future sales. This is the fourth such partnership, showing the technology is valued by big drugmakers.

    New cash and validation of the BrainTransporter platform directly improve BioArctic's finances and future earnings potential.

  • FDA approves at-home Leqembi autoinjector as starting dose US regulators approved a once-weekly under-the-skin Leqembi injection, given at home with an autoinjector, as a starting treatment for early Alzheimer's. Patients no longer need clinic infusions to begin therapy. Easier use should widen the number of patients who start and stay on the drug, lifting BioArctic's royalties.

    Broader and simpler access to Leqembi is the main long-term driver of BioArctic's royalty income.

  • Leqembi royalties up about 43% excluding one-off China stockpiling Leqembi global sales were 29.3 billion yen in Q2 2026, paying BioArctic 179 million Swedish kronor in royalties. That is about 10% higher than a year earlier, but last year included a one-time China stockpiling boost; stripping that out, royalties grew roughly 43%. Underlying demand for the drug is clearly rising.

    Royalty income is BioArctic's recurring revenue base, so its underlying growth rate is central to the investment case.

  • Q2 results show growing royalties but still a small operating loss BioArctic's Q2 revenue was 247.5 million kronor, mostly Leqembi royalties, but it still posted a small operating loss of 6.5 million kronor and a loss per share of 0.13 kronor. It also began an oncology collaboration with Mesenkia on a glioblastoma antibody treatment. Cash from Lilly and rising royalties fund research, but profits have not yet arrived.

    It shows the real counterweight: strong deal and royalty momentum, yet the company is not yet profitable.

July 2026
▲3

Lilly deal, Leqembi at-home approval and 43% royalty growth lift BioArctic

  • Lilly BrainTransporter deal brings $30M upfront and up to $770M milestones BioArctic signed a research deal with Eli Lilly combining its BrainTransporter brain-delivery technology with a Lilly neurodegeneration drug. It gets $30 million cash now and could receive up to $770 million more if milestones are met, plus royalties on future sales. This is the fourth such partnership, showing the technology is valued by big drugmakers.

    New cash and validation of the BrainTransporter platform directly improve BioArctic's finances and future earnings potential.

  • FDA approves at-home Leqembi autoinjector as starting dose US regulators approved a once-weekly under-the-skin Leqembi injection, given at home with an autoinjector, as a starting treatment for early Alzheimer's. Patients no longer need clinic infusions to begin therapy. Easier use should widen the number of patients who start and stay on the drug, lifting BioArctic's royalties.

    Broader and simpler access to Leqembi is the main long-term driver of BioArctic's royalty income.

  • Leqembi royalties up about 43% excluding one-off China stockpiling Leqembi global sales were 29.3 billion yen in Q2 2026, paying BioArctic 179 million Swedish kronor in royalties. That is about 10% higher than a year earlier, but last year included a one-time China stockpiling boost; stripping that out, royalties grew roughly 43%. Underlying demand for the drug is clearly rising.

    Royalty income is BioArctic's recurring revenue base, so its underlying growth rate is central to the investment case.

  • Q2 results show growing royalties but still a small operating loss BioArctic's Q2 revenue was 247.5 million kronor, mostly Leqembi royalties, but it still posted a small operating loss of 6.5 million kronor and a loss per share of 0.13 kronor. It also began an oncology collaboration with Mesenkia on a glioblastoma antibody treatment. Cash from Lilly and rising royalties fund research, but profits have not yet arrived.

    It shows the real counterweight: strong deal and royalty momentum, yet the company is not yet profitable.

Latest
▲3

Lilly deal, Leqembi at-home approval and 43% royalty growth lift BioArctic

  • Lilly BrainTransporter deal brings $30M upfront and up to $770M milestones BioArctic signed a research deal with Eli Lilly combining its BrainTransporter brain-delivery technology with a Lilly neurodegeneration drug. It gets $30 million cash now and could receive up to $770 million more if milestones are met, plus royalties on future sales. This is the fourth such partnership, showing the technology is valued by big drugmakers.

    New cash and validation of the BrainTransporter platform directly improve BioArctic's finances and future earnings potential.

  • FDA approves at-home Leqembi autoinjector as starting dose US regulators approved a once-weekly under-the-skin Leqembi injection, given at home with an autoinjector, as a starting treatment for early Alzheimer's. Patients no longer need clinic infusions to begin therapy. Easier use should widen the number of patients who start and stay on the drug, lifting BioArctic's royalties.

    Broader and simpler access to Leqembi is the main long-term driver of BioArctic's royalty income.

  • Leqembi royalties up about 43% excluding one-off China stockpiling Leqembi global sales were 29.3 billion yen in Q2 2026, paying BioArctic 179 million Swedish kronor in royalties. That is about 10% higher than a year earlier, but last year included a one-time China stockpiling boost; stripping that out, royalties grew roughly 43%. Underlying demand for the drug is clearly rising.

    Royalty income is BioArctic's recurring revenue base, so its underlying growth rate is central to the investment case.

  • Q2 results show growing royalties but still a small operating loss BioArctic's Q2 revenue was 247.5 million kronor, mostly Leqembi royalties, but it still posted a small operating loss of 6.5 million kronor and a loss per share of 0.13 kronor. It also began an oncology collaboration with Mesenkia on a glioblastoma antibody treatment. Cash from Lilly and rising royalties fund research, but profits have not yet arrived.

    It shows the real counterweight: strong deal and royalty momentum, yet the company is not yet profitable.

ACADIA Pharmaceuticals Inc (ACAD)

Q3 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

August 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

Latest
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.